| IPSEN S.A. PORT. EO 1 |
| Frankreich |
| Gesundheit |
| FR0010259150 / A0ESMG |
| I7G (Frankfurt) |
| FRA:I7G, ETR:I7G, I7G:GR |
| - |
| https://www.ipsen.com/ |
|
Ipsen S.A. is a French biopharmaceutical company headquartered in Paris, specializing in the development and commercialization of transformative medicines across three core therapeutic areas: oncology, rare diseases, and neuroscience. Founded in 1929..
>Volltext.. |
| 11974.42 Mio. EUR |
| 10969.27 Mio. EUR |
| 4120.86 Mio. EUR |
| 1975.04 Mio. EUR |
| 522.05 Mio. EUR |
| 6.31 EUR |
| 980.95 Mio. EUR |
| 2006.61 Mio. EUR |
| 1328.84 Mio. EUR |
| 1.14 |
| 13.63% |
| 14.45% |
| 1.6 EUR |
| 1.1% |
| 1.15% |
| 03.06.26 - 1.6€ 04.06.25 - 1.4€ >weitere anzeigen... |
| - |
| IPSEN |
| 09.10.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|